{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:33:03Z","timestamp":1788845583874,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010877","name":"Science, Technology and Innovation Commission of Shenzhen Municipality","doi-asserted-by":"publisher","award":["JCYJ20160229210357960"],"award-info":[{"award-number":["JCYJ20160229210357960"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010909","name":"Excellent Young Scientists Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010909","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001747","name":"Hong Kong Baptist University","doi-asserted-by":"publisher","award":["RC-IRCs\/17-18\/02"],"award-info":[{"award-number":["RC-IRCs\/17-18\/02"]}],"id":[{"id":"10.13039\/501100001747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFA0800802"],"award-info":[{"award-number":["2018YFA0800802"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304378"],"award-info":[{"award-number":["82304378"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["T12-201-20R"],"award-info":[{"award-number":["T12-201-20R"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2019B1515120089"],"award-info":[{"award-number":["2019B1515120089"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515110630"],"award-info":[{"award-number":["2020A1515110630"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002767","name":"Department of Science and Technology of Hunan Province","doi-asserted-by":"publisher","award":["2022WK2010"],"award-info":[{"award-number":["2022WK2010"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004853","name":"Chinese University of Hong Kong","doi-asserted-by":"publisher","award":["4054714"],"award-info":[{"award-number":["4054714"]}],"id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.omtn.2023.102073","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T02:31:46Z","timestamp":1699583506000},"page":"102073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["A bimolecular modification strategy for developing long-lasting bone anabolic aptamer"],"prefix":"10.1016","volume":"34","author":[{"given":"Huarui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sifan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaijian","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amu","family":"Gubu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongkang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7807-7695","authenticated-orcid":false,"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2023.102073_bib1","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nrd.2017.86","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2023.102073_bib2","doi-asserted-by":"crossref","first-page":"9500","DOI":"10.1021\/acsami.0c05750","article-title":"Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications","volume":"13","author":"Ni","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.omtn.2023.102073_bib3","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/s41467-022-29070-5","article-title":"Structural Insight into the MCM double hexamer activation by Dbf4-Cdc7 kinase","volume":"13","author":"Cheng","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2023.102073_bib4","doi-asserted-by":"crossref","first-page":"6453","DOI":"10.1093\/nar\/gkac366","article-title":"Ribosomal protein eL39 is important for maturation of the nascent polypeptide exit tunnel and proper protein folding during translation","volume":"50","author":"Micic","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2023.102073_bib5","article-title":"From selection hits to clinical leads: progress in aptamer discovery","volume":"5","author":"Maier","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2023.102073_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.biochi.2022.06.001","article-title":"Selection and characterization of DNA aptamers inhibiting a druggable target of osteoarthritis, ADAMTS-5","volume":"201","author":"Yu","year":"2022","journal-title":"Biochimie"},{"key":"10.1016\/j.omtn.2023.102073_bib7","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1021\/acsabm.2c00324","article-title":"Self-Assembly of DNA Tiles with G-Quadruplex DNAzyme Catalytic Activity for Sensing Applications","volume":"5","author":"Wang","year":"2022","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.omtn.2023.102073_bib8","doi-asserted-by":"crossref","first-page":"6134","DOI":"10.1038\/s41467-020-19755-0","article-title":"Ultrasensitive antibody-aptamer plasmonic biosensor for malaria biomarker detection in whole blood","volume":"11","author":"Minopoli","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2023.102073_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21113860","article-title":"Design, Synthesis and Characterization of Cyclic NU172 Analogues: A Biophysical and Biological Insight","volume":"21","author":"Riccardi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2023.102073_bib10","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.tibtech.2023.05.005","article-title":"Modified nucleic acid aptamers: development, characterization, and biological applications","volume":"41","author":"Ji","year":"2023","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.omtn.2023.102073_bib11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1517\/14728214.2015.1113254","article-title":"What is the future of PEGylated therapies?","volume":"20","author":"Swierczewska","year":"2015","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.omtn.2023.102073_bib12","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1038\/s41467-022-31997-8","article-title":"Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation","volume":"13","author":"Yu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2023.102073_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1048148","article-title":"Strategies for developing long-lasting therapeutic nucleic acid aptamer targeting circulating protein: The present and the future","volume":"10","author":"Zhang","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omtn.2023.102073_bib14","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1038\/s41598-022-08759-z","article-title":"Targeting lung cancer cells with MUC1 aptamer-functionalized PLA-PEG nanocarriers","volume":"12","author":"Shahrad","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2023.102073_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202107852","article-title":"PEG-Like Brush Polymer Conjugate of RNA Aptamer That Shows Reversible Anticoagulant Activity and Minimal Immune Response","volume":"34","author":"Ozer","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.omtn.2023.102073_bib16","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jaci.2016.04.058","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer","volume":"138","author":"Povsic","year":"2016","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.omtn.2023.102073_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.biomaterials.2018.06.012","article-title":"Annealing novel nucleobase-lipids with oligonucleotides or plasmid DNA based on H-bonding or pi-pi interaction: Assemblies and transfections","volume":"178","author":"Ma","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2023.102073_bib18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.biomaterials.2018.12.033","article-title":"Structural optimization and additional targets identification of antisense oligonucleotide G3139 encapsulated in a neutral cytidinyl-lipid combined with a cationic lipid in\u00a0vitro and in\u00a0vivo","volume":"197","author":"Ma","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2023.102073_bib19","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.apsb.2022.01.012","article-title":"Drug discovery of sclerostin inhibitors","volume":"12","author":"Yu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.omtn.2023.102073_bib20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.mam.2011.12.002","article-title":"Human serum albumin: from bench to bedside","volume":"33","author":"Fanali","year":"2012","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.omtn.2023.102073_bib21","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1893888","article-title":"Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in\u00a0vitro and in\u00a0vivo","volume":"13","author":"Mester","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.omtn.2023.102073_bib22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.omtn.2023.102073_bib23","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/1869","article-title":"Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites","volume":"5","author":"Curry","year":"1998","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.omtn.2023.102073_bib24","doi-asserted-by":"crossref","first-page":"22804","DOI":"10.1074\/jbc.M100575200","article-title":"Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I","volume":"276","author":"Petitpas","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2023.102073_bib25","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/bcp.12220","article-title":"Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon","volume":"77","author":"Verhoef","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.omtn.2023.102073_bib26","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1182\/blood-2018-01-830901","article-title":"Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition","volume":"132","author":"Wu","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2023.102073_bib27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.abb.2015.05.018","article-title":"Fatty acid binding into the highest affinity site of human serum albumin observed in molecular dynamics simulation","volume":"579","author":"Rizzuti","year":"2015","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.omtn.2023.102073_bib28","first-page":"650","article-title":"Fatty Acid Binding to Human Serum Albumin in Blood Serum Characterized by EPR Spectroscopy","volume":"8","author":"Haeri","year":"2019","journal-title":"Chemistry (Rajkot, India)"},{"key":"10.1016\/j.omtn.2023.102073_bib29","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1248\/cpb.59.860","article-title":"Steric and allosteric effects of fatty acids on the binding of warfarin to human serum albumin revealed by molecular dynamics and free energy calculations","volume":"59","author":"Fujiwara","year":"2011","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.omtn.2023.102073_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180404","article-title":"Long chain fatty acids alter the interactive binding of ligands to the two principal drug binding sites of human serum albumin","volume":"12","author":"Yamasaki","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2023.102073_bib31","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.2042-7158.1996.tb03990.x","article-title":"Influence of fatty acids on the binding of warfarin and phenprocoumon to human serum albumin with relation to anticoagulant therapy","volume":"48","author":"Vorum","year":"1996","journal-title":"J.\u00a0Pharm. Pharmacol."},{"key":"10.1016\/j.omtn.2023.102073_bib32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1043-2760(00)00257-5","article-title":"The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function","volume":"11","author":"Hertzel","year":"2000","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.omtn.2023.102073_bib33","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.7150\/thno.63177","article-title":"Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta mice","volume":"12","author":"Wang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.omtn.2023.102073_bib34","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/er.2011-1060","article-title":"Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases","volume":"33","author":"Ke","year":"2012","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.omtn.2023.102073_bib35","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1210\/en.2011-0252","article-title":"Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats","volume":"152","author":"Li","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.omtn.2023.102073_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201903451","article-title":"A Loop-Based and AGO-Incorporated Virtual Screening Model Targeting AGO-Mediated miRNA-mRNA Interactions for Drug Discovery to Rescue Bone Phenotype in Genetically Modified Mice","volume":"7","author":"Zhuo","year":"2020","journal-title":"Adv. Sci."},{"key":"10.1016\/j.omtn.2023.102073_bib37","doi-asserted-by":"crossref","first-page":"12143","DOI":"10.1074\/jbc.RA120.014168","article-title":"Structure-activity analysis of truncated albumin-binding domains suggests new lead constructs for potential therapeutic delivery","volume":"295","author":"Wang","year":"2020","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2023.102073_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/srep15632","article-title":"Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength of Intact Bones in Adult Male Rats","volume":"5","author":"Suen","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2023.102073_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11505","article-title":"A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair","volume":"7","author":"Florio","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2023.102073_bib40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.omtn.2023.102073_bib41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drudis.2020.10.010","article-title":"Artificial intelligence in drug discovery and development","volume":"26","author":"Paul","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.omtn.2023.102073_bib42","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/s41467-020-15113-2","article-title":"Aptamer-based optical manipulation of protein subcellular localization in cells","volume":"11","author":"Xie","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2023.102073_bib43","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/jacs.9b10755","article-title":"Molecular Self-Assembly of Bioorthogonal Aptamer-Prodrug Conjugate Micelles for Hydrogen Peroxide and pH-Independent Cancer Chemodynamic Therapy","volume":"142","author":"Xuan","year":"2020","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.omtn.2023.102073_bib44","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/bmc.3476","article-title":"Development and validation of an RP-HPLC method for the quantitation of odanacatib in rat and human plasma and its application to a pharmacokinetic study","volume":"29","author":"Police","year":"2015","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.omtn.2023.102073_bib45","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1210\/jc.2013-1688","article-title":"Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women","volume":"99","author":"Anderson","year":"2014","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.omtn.2023.102073_bib46","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1021\/ja049795q","article-title":"A highly discriminating quencher-free molecular beacon for probing DNA","volume":"126","author":"Hwang","year":"2004","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.omtn.2023.102073_bib47","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1021\/acs.jmedchem.7b00969","article-title":"Relevance of Half-Life in Drug Design","volume":"61","author":"Smith","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.omtn.2023.102073_bib48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF01059626","article-title":"Clearance concepts in pharmacokinetics","volume":"1","author":"Rowland","year":"1973","journal-title":"J.\u00a0Pharmacokinet. Biopharm."},{"key":"10.1016\/j.omtn.2023.102073_bib49","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2885.2004.00605.x","article-title":"Plasma clearance","volume":"27","author":"Toutain","year":"2004","journal-title":"J.\u00a0Vet. Pharmacol. Therapeut."},{"key":"10.1016\/j.omtn.2023.102073_bib50","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1161\/ATVBAHA.111.237529","article-title":"ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion","volume":"32","author":"Siller-Matula","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.omtn.2023.102073_bib51","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1046\/j.1365-2125.2003.01944.x","article-title":"Bioavailability of dexmedetomidine after extravascular doses in healthy subjects","volume":"56","author":"Anttila","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.omtn.2023.102073_bib52","first-page":"3312","article-title":"Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals","volume":"9","author":"Chow","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2023.102073_bib53","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nm.2617","article-title":"A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2023.102073_bib54","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nm.3791","article-title":"Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy","volume":"21","author":"Liang","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2023.102073_bib55","article-title":"Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation","volume":"7","author":"Li","year":"2016","journal-title":"Nat. Commun."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123002913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123002913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:22:56Z","timestamp":1762600976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253123002913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":55,"alternative-id":["S2162253123002913"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2023.102073","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A bimolecular modification strategy for developing long-lasting bone anabolic aptamer","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2023.102073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"102073"}}